ABIVAX press release
Abivax publishes its 2023 annual results and presents a progress update on the activity.
• Financing of 500 million euros in 2023, including a capital increase of 130 million euros, two structured financing operations for a total amount of 150 million euros and the IPO on the Nasdaq Global Market of an amount of 223.3 million euros
• Sufficient funds to finance operations through the fourth quarter of 2025, following the announcement of topline results from the phase 3 induction study of the ABTECT program of obefazimod in ulcerative colitis (UC)
• Establishment of an operational infrastructure in the United States and Europe to advance the Company’s ongoing clinical and preclinical programs